Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    03350815
Previous Study | Return to List | Next Study

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03350815
Recruitment Status : Recruiting
First Posted : November 22, 2017
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Drug: 150 mg open-label secukinumab Drug: 150 mg double-blinded secukinumab Drug: 300 mg double-blinded secukinumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Patients and Investigators will be blinded to the secukinumab dose during Treatment Period 2.
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)
Actual Study Start Date : March 13, 2018
Estimated Primary Completion Date : November 27, 2020
Estimated Study Completion Date : November 27, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Secukinumab

Arm Intervention/treatment
Active Comparator: Responders
Patients achieving an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (total score <1.3) at both Week 12 and Week 16.
Drug: 150 mg open-label secukinumab
All patients in Treatment Period 1 will receive 150 mg open-label secukinumab.
Other Name: AIN457

Drug: 150 mg double-blinded secukinumab
Treatment Period 2
Other Name: AIN457

Active Comparator: Inadequate responders
Patients who have active disease, defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) total score of >1.3 at both Week 12 and Week 16, and who do achieve a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.
Drug: 150 mg open-label secukinumab
All patients in Treatment Period 1 will receive 150 mg open-label secukinumab.
Other Name: AIN457

Drug: 150 mg double-blinded secukinumab
Treatment Period 2
Other Name: AIN457

Drug: 300 mg double-blinded secukinumab
Treatment Period 2
Other Name: AIN457

Active Comparator: Non-responders

Patients who exhibit no change or an increase (worsening) from baseline in total Ankylosing Spondylitis Disease Activity Score (ASDAS) score at either Week 12 or Week 16.

Non-responders will not enter Treatment Period 2. Non-responders will be discontinued from the study at Week 16.

Drug: 150 mg open-label secukinumab
All patients in Treatment Period 1 will receive 150 mg open-label secukinumab.
Other Name: AIN457




Primary Outcome Measures :
  1. The proportion of participants who achieve inactive disease based on the Ankylosing Spondylitis Disease Activity Score (ASDAS) measure [ Time Frame: Week 52 ]
    An ASDAS inactive disease response is a score of <1.3 on a composite index to assess disease activity in Ankylosing Spondylitis. Parameters include spinal pain, the patient's global assessment of disease activity, peripheral pain/swelling, duration of morning stiffness and C-reactive protein (CRP) in mg/L. In this study, ASDAS is used to estimate the difference in response between 150mg and 300mg of secukinumab.


Secondary Outcome Measures :
  1. The proportion of participants who achieve a clinically important improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS) scale [ Time Frame: Week 52 ]
    A change from baseline in ASDAS score of ≥1.1 is considered a clinically important improvement in disease activity in Ankylosing Spondylitis. In this study, ASDAS is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  2. Change over time in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [ Time Frame: Week 52 ]
    BASDAI is a validated assessment tool using 0 through 10 scales (0 indicating "no problem" and 10 indicating "worst problem"), to characterize six clinical domains pertaining to five major symptoms of AS perceived by the patients. Computed composite scores of 4 or greater indicate suboptimal disease control. In this study, BASDAI is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  3. Proportion of patients who achieve Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI-50) [ Time Frame: Week 52 ]
    BASDAI-50 represents a change from baseline (improvement) of at least 50% in BASDAI score. In this study, BASDAI is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  4. The proportion of participants who achieve an ASAS 20 response (Assessment of SpondyloArthritis International Society criteria) [ Time Frame: Week 52 ]
    ASAS 20 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 20% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS20 is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  5. The proportion of participants who achieve an ASAS 40 response [ Time Frame: Week 52 ]
    ASAS 40 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 40% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS40 is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  6. The proportion of patients who achieve an ASAS partial remission [ Time Frame: Week 52 ]
    The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. In this study, ASAS partial remission is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  7. Change in ASAS - Health Index over time [ Time Frame: Week 52 ]
    The ASAS-HI is a self-administered questionnaire and measures functioning and health over 17 aspects of health and 9 environmental factors in patients with spondyloarthritis. Patients score each item as "I agree" and "I do not agree". In this study, ASAS-HI is used to estimate the difference in response between 150mg and 300mg of secukinumab.

  8. Change in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue over time [ Time Frame: Week 52 ]

    The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. It is administered at Visits 4

    - 19. ". In this study, FACIT-Fatigue is used to estimate the difference in response between 150mg and 300mg of secukinumab.


  9. Number of participants with treatment-related adverse events or serious adverse events [ Time Frame: Week 52 ]
    These assessments will be implemented in terms of physical examination and vital signs outcomes, clinical laboratory results, nature and frequency of the observed adverse events and serious adverse events, frequency and severity of any injection site reactions, ECG outcomes and the detection of immunogenicity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent
  2. Male or non-pregnant, non-lactating female patients at least 18 years of age
  3. Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS
  4. Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) ≥ 4 (0-10) at baseline
  5. Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at baseline
  6. Total back pain as measured by visual analog scale (VAS) ≥ 40 mm (0-100 mm) at baseline
  7. Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications
  8. Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit
  9. Patients who have been on a tumor necrosis factor alpha (TNFα) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFα agent

Key Exclusion Criteria:

  1. Total ankylosis of the spine
  2. Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.
  3. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
  4. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician.
  5. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFα
  6. Patients who have taken more than one anti-TNFα agent
  7. Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline
  8. Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline
  9. Previous treatment with any cell-depleting therapies
  10. Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350815


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

  Hide Study Locations
Locations
Layout table for location information
United States, Arkansas
Novartis Investigative Site Recruiting
Jonesboro, Arkansas, United States, 72437
United States, California
Novartis Investigative Site Recruiting
Fullerton, California, United States, 92835
Novartis Investigative Site Recruiting
Huntington Beach, California, United States, 92646
Novartis Investigative Site Recruiting
Loma Linda, California, United States, 92354
Novartis Investigative Site Recruiting
Palm Desert, California, United States, 92260
Novartis Investigative Site Recruiting
Tustin, California, United States, 92780
Novartis Investigative Site Recruiting
Upland, California, United States, 91786
United States, Connecticut
Novartis Investigative Site Recruiting
Danbury, Connecticut, United States, 06810
United States, Florida
Novartis Investigative Site Recruiting
Aventura, Florida, United States, 33180
Novartis Investigative Site Recruiting
Boca Raton, Florida, United States, 33486
Novartis Investigative Site Recruiting
Brandon, Florida, United States, 33511
Novartis Investigative Site Recruiting
DeLand, Florida, United States, 32720
Novartis Investigative Site Recruiting
Gainesville, Florida, United States, 32608
Novartis Investigative Site Recruiting
Orlando, Florida, United States, 32806
Novartis Investigative Site Recruiting
Orlando, Florida, United States, 32810
Novartis Investigative Site Recruiting
Plantation, Florida, United States, 33324
Novartis Investigative Site Recruiting
Saint Petersburg, Florida, United States, 33705
Novartis Investigative Site Recruiting
Tamarac, Florida, United States, 33321
Novartis Investigative Site Recruiting
Tampa, Florida, United States, 33609
United States, Georgia
Novartis Investigative Site Recruiting
Duluth, Georgia, United States, 30096
United States, Illinois
Novartis Investigative Site Recruiting
Springfield, Illinois, United States, 62703
Novartis Investigative Site Recruiting
Vernon Hills, Illinois, United States, 60061
United States, Indiana
Novartis Investigative Site Recruiting
Evansville, Indiana, United States, 47715
United States, Louisiana
Novartis Investigative Site Recruiting
Monroe, Louisiana, United States, 71203
United States, Maryland
Novartis Investigative Site Recruiting
Hagerstown, Maryland, United States, 21740
Novartis Investigative Site Recruiting
Wheaton, Maryland, United States, 20902
United States, Massachusetts
Novartis Investigative Site Recruiting
Boston, Massachusetts, United States, 02111
United States, Michigan
Novartis Investigative Site Recruiting
Ann Arbor, Michigan, United States, 48109 5271
Novartis Investigative Site Recruiting
Saint Clair Shores, Michigan, United States, 48081
United States, Minnesota
Novartis Investigative Site Recruiting
Edina, Minnesota, United States, 55435
United States, Missouri
Novartis Investigative Site Recruiting
Springfield, Missouri, United States, 65810
United States, New Jersey
Novartis Investigative Site Recruiting
Midland Park, New Jersey, United States, 07432
Novartis Investigative Site Recruiting
Voorhees, New Jersey, United States, 08043
United States, New Mexico
Novartis Investigative Site Recruiting
Albuquerque, New Mexico, United States, 87102
Novartis Investigative Site Recruiting
Santa Fe, New Mexico, United States, 87505
United States, New York
Novartis Investigative Site Recruiting
Brooklyn, New York, United States, 11201
Novartis Investigative Site Recruiting
New York, New York, United States, 10016
Novartis Investigative Site Recruiting
Orchard Park, New York, United States, 14127
Novartis Investigative Site Recruiting
Potsdam, New York, United States, 13676
United States, North Dakota
Novartis Investigative Site Recruiting
Minot, North Dakota, United States, 58701
United States, Ohio
Novartis Investigative Site Recruiting
Cincinnati, Ohio, United States, 45219
Novartis Investigative Site Recruiting
Dayton, Ohio, United States, 45402
Novartis Investigative Site Recruiting
Middleburg Heights, Ohio, United States, 44130
United States, Oklahoma
Novartis Investigative Site Recruiting
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
Novartis Investigative Site Recruiting
Corvallis, Oregon, United States, 97330
Novartis Investigative Site Recruiting
Portland, Oregon, United States, 97239
United States, Pennsylvania
Novartis Investigative Site Recruiting
Duncansville, Pennsylvania, United States, 16635
Novartis Investigative Site Recruiting
Wexford, Pennsylvania, United States, 15090
United States, South Carolina
Novartis Investigative Site Recruiting
Charleston, South Carolina, United States, 29460
Novartis Investigative Site Recruiting
Columbia, South Carolina, United States, 29204
United States, Tennessee
Novartis Investigative Site Recruiting
Jackson, Tennessee, United States, 38305
Novartis Investigative Site Recruiting
Memphis, Tennessee, United States, 38119
United States, Texas
Novartis Investigative Site Recruiting
Beaumont, Texas, United States, 77701
Novartis Investigative Site Recruiting
Colleyville, Texas, United States, 76034
Novartis Investigative Site Recruiting
Dallas, Texas, United States, 75231
Novartis Investigative Site Recruiting
Houston, Texas, United States, 77025
Novartis Investigative Site Recruiting
Houston, Texas, United States, 77089
Novartis Investigative Site Recruiting
Mesquite, Texas, United States, 75150
United States, Utah
Novartis Investigative Site Recruiting
Salt Lake City, Utah, United States, 84132
United States, Washington
Novartis Investigative Site Recruiting
Seattle, Washington, United States, 98104
Novartis Investigative Site Recruiting
Seattle, Washington, United States, 98195
Novartis Investigative Site Recruiting
Spokane, Washington, United States, 99204
United States, West Virginia
Novartis Investigative Site Recruiting
Charleston, West Virginia, United States, 25304
United States, Wisconsin
Novartis Investigative Site Recruiting
Manitowoc, Wisconsin, United States, 54220
Novartis Investigative Site Recruiting
Onalaska, Wisconsin, United States, 54650
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03350815     History of Changes
Other Study ID Numbers: CAIN457FUS06
First Posted: November 22, 2017    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Ankylosing spondylitis, ASDAS inactive disease, secukinumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs